ARTA
NBIX icon

A.R.T. Advisors’s Neurocrine Biosciences NBIX Stock Holding History

A.R.T. Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,743
Closed -$1.26M – 649
2019
Q4 		$1.26M Buy
+11,743
New +$1.23M 0.06% 460
2019
Q2 		– Sell
-8,267
Closed -$728K – 1534
2019
Q1 		$728K Sell
8,267
-3,500
-30% -$293K 0.04% 600
2018
Q4 		$840K Sell
11,767
-4,833
-29% -$463K 0.05% 503
2018
Q3 		$2.04M Buy
+16,600
New +$1.88M 0.09% 286
2018
Q2 		– Sell
-37,600
Closed -$3.12M – 1654
2018
Q1 		$3.12M Sell
37,600
-55,100
-59% -$4.65M 0.13% 234
2017
Q4 		$7.19M Buy
+92,700
New +$6.32M 0.32% 39
2017
Q1 		– Sell
-53,600
Closed -$2.07M – 1611
2016
Q4 		$2.07M Buy
53,600
+46,100
+615% +$2.09M 0.12% 253
2016
Q3 		$379K Sell
7,500
-21,673
-74% -$1.08M 0.12% 262
2016
Q2 		$1.32M Buy
+29,173
New +$1.34M 0.07% 447
2016
Q1 		– Sell
-62,105
Closed -$3.51M – 1559
2015
Q4 		$3.51M Sell
62,105
-46,100
-43% -$2.34M 0.17% 146
2015
Q3 		$4.3M Buy
108,205
+52,633
+95% +$2.54M 0.16% 166
2015
Q2 		$2.65M Buy
55,572
+3,329
+6% +$141K 0.09% 352
2015
Q1 		$2.07M Buy
+52,243
New +$1.87M 0.07% 383
2014
Q1 		– Sell
-151,584
Closed -$1.42M – 1485
2013
Q4 		$1.42M Buy
151,584
+117,440
+344% +$1.15M 0.08% 373
2013
Q3 		$386K Sell
34,144
-76,047
-69% -$1.05M 0.02% 874
2013
Q2 		$1.47M Buy
+110,191
New +$1.35M 0.05% 486

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

A.R.T. Advisors's NBIX Position: Q1 2020 in Review

A.R.T. Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 11,743 shares — an estimated $1.26M sold.

A.R.T. Advisors first reported a position in NBIX in Q2 2013 and held it in 16 quarters. The position peaked at $7.19M in Q4 2017. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • A.R.T. Advisors reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 11,743 Neurocrine Biosciences shares in Q1 2020, an estimated $1.26M.
  • A.R.T. Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 16 quarters.
  • A.R.T. Advisors's Neurocrine Biosciences position peaked at $7.19M in Q4 2017.
  • 368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.